1. Medtech Insight
  2. >>Geography
  3. >>Europe

Torax Medical’s Linx System: A New Approach To GERD

Although many companies have fallen short in developing a truly effective minimally invasive device for the treatment of chronic GERD, Torax Medical’s co-founder, president, and CEO Todd Berg believes the company’s new Linx Reflux Management System will find success because it is fundamentally unlike anything else that has come before. In an interview with Medtech Insight, Berg discussed the Linx device, the GERD market, and the company’s strategies for success.

Most of the 20 million adults in the US who suffer from chronic gastroesophageal reflux disease (GERD) hope to find symptomatic relief from their “heartburn” with first-line nonsurgical treatments, like raising the head of the bed, losing weight, eating smaller meals, or taking medications such as antacids or proton-pump inhibitors (PPIs). However, despite high-dose medications, GERD-related symptoms persist in almost 40% of patients, and less than 1% of these patients resort to having a laparoscopic Nissen fundoplication, an invasive, but effective surgical procedure that involves wrapping the upper portion of the stomach or fundus around the bottom of the esophagus.

Over the last decade, medical device manufacturers have been trying to develop an effective minimally invasive device for the treatment of GERD that fills the gap between pharmacological acid suppression...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

EU Finalizes Framework For Joint Clinical Assessments Of High-Risk Devices

 
• By Amanda Maxwell

Second submission window for joint scientific consultations on a procedure to help prepare for joint clinical assessments will open from 2 to 30 June 2025.

UK Take Care! Regulatory And Market Access Reforms Must Not Shut Out Medtech Growth

 
• By Ashley Yeo

Speakers at a recent UK medtech outlook conference voiced optimism about the sector’s prospects, but warned that cost burdens, over-regulation and lengthy processes will impede the capacity of local SMEs to innovate. Only 10% of NHS procured medtech comes from UK manufacturers.

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 
• By Natasha Barrow

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

Industry Execs Talk Tariff Turbulence During MD&M East

 
• By Brian Bossetta

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.

More from Geography

Get Ready For International Harmonization Before Approaching QMSR Deadline, Says Regulatory Expert

 
• By Brian Bossetta

During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.

UK Take Care! Regulatory And Market Access Reforms Must Not Shut Out Medtech Growth

 
• By Ashley Yeo

Speakers at a recent UK medtech outlook conference voiced optimism about the sector’s prospects, but warned that cost burdens, over-regulation and lengthy processes will impede the capacity of local SMEs to innovate. Only 10% of NHS procured medtech comes from UK manufacturers.

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 
• By Natasha Barrow

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.